atorvastatin (Lipitor)

ApprovedTerminated

0 views this week 0 watching💤 Quiet

Interest: 35/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

✓

Phase 2

✓

Phase 3

Approved

Indication / Disease

Aortic Valve Stenosis

Conditions

Aortic Valve Stenosis

Trial Timeline

Aug 1, 2000 → Apr 26, 2010

NCT ID

NCT00590135

About atorvastatin (Lipitor)

atorvastatin (Lipitor) is a approved stage product being developed by Pfizer for Aortic Valve Stenosis. The current trial status is terminated. This product is registered under clinical trial identifier NCT00590135. Target conditions include Aortic Valve Stenosis.

What happened to similar drugs?

5 of 13 similar drugs in Aortic Valve Stenosis were approved

Approved (5) Terminated (3) Active (6)

❌Apixaban 5 MG + Apixaban 2.5 MG + WarfarinArtivionPhase 3

🔄EdoxabanDaiichi SankyoPhase 3

✅NOAC + DAPTDaiichi SankyoApproved

🔄Rosuvastatin + PlaceboAstraZenecaPhase 3

🔄candesartan + placeboAstraZenecaPhase 3

✅SugammadexMerckApproved

✅bisoprolol + placeboMerckApproved

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (3)

NCT ID	Phase	Status	Start	Completion	Indication
NCT00442325	Approved	Completed	Jan 1, 2003	Feb 1, 2004	Coronary Arteriosclerosis
NCT00442845	Approved	Completed	Jan 1, 2003	Feb 1, 2004	Coronary Arteriosclerosis
NCT00590135	Approved	Terminated	Aug 1, 2000	Apr 26, 2010	Aortic Valve Stenosis

Competing Products

20 competing products in Aortic Valve Stenosis

See all competitors

Product	Company	Stage	Hype Score
Apixaban 5 MG + Apixaban 2.5 MG + Warfarin	Artivion	Phase 3	26
Edoxaban	Daiichi Sankyo	Phase 3	36
NOAC + DAPT	Daiichi Sankyo	Approved	43
Ticagrelor + Placebo	AstraZeneca	Phase 2	35
Rosuvastatin + Placebo	AstraZeneca	Phase 3	40
candesartan + placebo	AstraZeneca	Phase 3	36
Sugammadex	Merck	Approved	43
bisoprolol + placebo	Merck	Approved	35
Metformin Glucophage 500mg (IR) tablets M90 + Placebo Oral Tablet	Merck	Phase 2/3	42
Pelacarsen (TQJ230) 80mg + Matching placebo	Novartis	Phase 2	42
fluvastatin	Novartis	Phase 2	31
ACZ885 + Placebo	Novartis	Phase 2	27
Evolocumab + Placebo	Amgen	Phase 1	36
Apixaban + Standard of care	Pfizer	Phase 3	40
Ataciguat + Placebo	Sanofi	Phase 1	29
Ataciguat (HMR1766)	Sanofi	Phase 2	35
Haemocomplettan® P + Saline solution	CSL	Phase 2	35
Rivaroxaban (Xarelto, BAY59-7939) + Acetylsalicylic Acid (ASA) + Clopidogrel + Rivaroxaban (Xarelto, BAY59-7939) + Vitamin K antagonist (VKA)	Bayer	Phase 3	29
Acetylsalicylic acid + Clopidogrel + Rivaroxaban	Bayer	Phase 3	37
Desflurane	Baxter	Approved	36